Naltrexone for opioid use disorders a review of clinical effectiveness, cost-effectiveness, and guidelines

The Food and Drug Administration in the U.S. approved naltrexone (XR-NTX) in 2010, however, in Canada extended-release naltrexone is only available through the Health Canada's Special Access Programme or for research. Given the relative novelty of XR-NTX, its effectiveness compared with oral na...

Full description

Bibliographic Details
Main Authors: Jahagirdar, Deepa, Wright, Mary-Doug (Author)
Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) Canadian Agency for Drugs and Technologies in Health July 4, 2017, 2017
Edition:Version 1.0
Series:CADTH rapid response report: summary with critical appraisal
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Table of Contents:
  • Includes bibliographical references